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Key points 
 
The development and application of Artificial Intelligence to Radiology requires an approach which 
encompasses a health system.  The UK government and NHS are creating an ecosystem to facilitate 
academic/industrial partnerships aimed at accelerating the creation of relevant and robust AI tools 
which will improve the development and delivery of healthcare imaging. A series of recent initiatives 
are described which will drive the development and adoption of AI in clinical imaging. 
 
 
 
 
 
 
 
 
 
 
  
Manuscript
 
 
The development of ever more sophisticated imaging technologies, such as computerised 
tomography (CT), Magnetic Resonance Imaging (MRI), Ultrasound and Positron Emission 
Tomography (PET), has led to a significant increase in the amount of data generated per patient[1]. 
At the same time, healthcare systems around the world are struggling to integrate and analyse this 
wealth of information, due to a shortage of trained radiologists and the sheer size and complexity of 
the datasets.  
 
Academia and industry are focusing on developing artificial intelligence (AI) techniques に 
encompassing machine learning (ML) and deep learning (DL) in particular に for analysing, 
interpreting, categorising and annotating clinical images. Progress in AI imaging technology is being 
driven by the rapidly expanding processing power of GPUs, falling costs of computing and data 
storage, the availability of large datasets for training and significant financial input from private and 
commercial investors and government sources.  
 
However, while AI has the potential to transform clinical imaging practice around the world by 
improving productivity and performance, there are significant issues that need to be resolved before 
imaging records are used at scale for training and AI is adopted in clinical practice. Although our 
focus is on the UK landscape, the challenges we face are relevant to the international research 
community of academic, clinical and industry partners working to speed the translation of AI imaging 
technologies into routine clinical practice. 
 
The value and pitfalls of AI in imaging are increasingly well-rehearsed in the literature [2,3]. It is clear 
that for the potential of AI in imaging to be realised, a whole-systems approach is required, which 
supports ready access to well-curated, annotated, data-sets by a skilled multi-disciplinary workforce, 
in a manner which is trusted by patients and the public and which enables the development and 
robust evaluation of novel analytical techniques. 
 
Bringing the power of AI to bear on clinical imaging is a multidisciplinary effort, requiring close 
collaboration between academic researchers, clinicians, industry, government agencies, healthcare 
professionals and patients to develop solutions that are safe, effective and integrate into clinical 
workflows. Engineering these partnerships and creating a research ecosystem in which they can 
flourish will rely on strategic direction and investment from national bodies, including government-
funded research organisations, industry and professional societies. 
 
 
Creating an ecosystem 
In the UK, three linked elements of an emerging ecosystem to deliver AI for imaging are of note: the 
recent Life Sciences Sector Deal [4] sets out an investment plan for the sector which includes 
investment in AI, to be delivered in partnership with industry and academia, by UK Research & 
Innovation (UKRI), aimed at placing the UK at the forefront of AI and data revolution; the National 
Institute for Health Research [5] - probably the world's largest integrated health research system, 
with more than £500m pa of research infrastructure embedded in the NHS designed to deliver high 
quality research at pace - is evolving in order to ensure the health system is well-placed to deliver 
high quality studies of AI in imaging; and NHSX [6], which  brings together the Department of Health 
and Social Care, NHS England and NHS Improvement with oversight of NHS Digital to drive 
transformation of health services by digital technology, with a particular focus on setting standards 
and developing platforms, thereby providing a framework for the development and adoption of AI in 
health.l  
 
Several specific initiatives are now underway; funded by the industrial challenge strategy fund, UKRI 
ran a funding competition in 2018 for £50m (~$65 million) to create a network of academic centres 
working with industry and focusing on developing AI in radiology and digital pathology for the NHS. 
A further £33 million (~$42 million) in funding was leveraged from universities, charities and 
companies ranging from small start-ups to major multinational companies [7]. Based in Leeds, 
Oxford, Coventry, Glasgow and London に but each with partners across many parts of the UK に the 
centres will develop AI for radiology and digital pathology. Working with NIHR, the five funded 
academic/industrial partnerships have been charged with delivering AI tools for clinical testing 
within the NHS in a three year time frame.   
  
While much of the attention in AI is focused on data and algorithm development, it is essential to 
remember the importance of skilled scientists and clinicians. This requires investment in 
multidisciplinary training programmes spanning the entire career pathway from studentships to 
fellowships and beyond, covering both clinical and non-clinical researchers. More should be done to 
encourage cross-disciplinary talent transfer, not just for medical doctors moving into AI research but 
also bringing physicists, mathematicians, engineers and computer scientists into closer proximity 
with biomedical researchers. This could extend to cross-disciplinary degrees, fellowships or even 
clinical placements to encourage people with AI skills to move into medical imaging. In February 
2019, UKRI announced funding awards of £100m to create 16 new Centres for Doctoral Training 
(CDTs) based at 14 UK universities with 300 partners, including AstraZeneca, Google and Rolls-Royce, 
and NHS trusts [8]. Project partners are investing £78 million in cash or in-kind contributions and 
partner universities are committing a further £23 million, resulting in an overall investment of more 
than £200 million. Applying AI to healthcare, including imaging, is an important element of the 
programme. This CDT platform should provide numerous opportunities to promote the 
interdisciplinary exchange that is vital for AI in imaging to flourish. The NIHR is also working with 
UKRI (Health Data Research UK) to develop a clinical academic development group in health data 
science which will help address some of these challenges. 
 
One important issue to be considered is the financial incentives available. Given that AI-based 
companies can offer significantly higher salaries than those available for academic researchers, 
developing effective partnerships with industry will be an important means of developing and 
retaining talent as the field grows. In the UK, UKRI and the NIHR now have a range of fellowship 
programmes which encourage cross-disciplinary working and industry placements, whilst an NIHR-
wide imaging programme also aims to support the development of a trained imaging research 
workforce in the NHS. 
 
There is a risk that recruitment into training programmes will be hampered by misplaced concerns 
that radiology will become redundant thanks to the advent of AI technologies, further depressing 
these disciplines that are already struggling. Instead, we must focus on promoting the model of the 
けIWﾐデ;┌ヴげ に a highly trained human working together with an AI to achieve more than would be 
possible alone. The Royal College of Radiologists, responsible for training standards is actively 
engaged in the development of AI and is ensuring the workforce is appropriately informed.  
 
Building a pipeline for development and validation 
There are two main challenges to be overcome when bringing AI techniques into clinical imaging: 
development of the tools themselves and their subsequent clinical validation and approval. These 
two strands must run in parallel and be closely intertwined に there is no point developing an 
impressive algorithm if it cannot be integrated into day-to-day service delivery, demonstrate its 
effectiveness and utility in real life situations and meet the conditions for regulatory approval. 
Furthermore, any AI-based imaging system must fit seamlessly into established clinical workflows に 
for example, integrating into existing workstations rather than operating in a standalone unit に 
otherwise it is unlikely to be widely adopted. It also has to demonstrate increased productivity, 
better patient outcomes and cost effectiveness, particularly in settings with stretched healthcare 
budgets.  The developing role of NHSX, working in partnership with key partners, including the Royal 
College of Radiologists, is likely to be particularly important. 
 
The most significant limiting factor in the development of AI technologies is the availability of 
sufficiently large, good quality training data. Keeping images in the AI pipeline is crucial for human 
interpretation and validation of resulting algorithms. Ideally, datasets should be uniformly acquired 
with standardised protocols across all sources, consistently annotated and anonymised or pseudo-
anonymised, depending on where and how they will be used. Annotation currently requires human 
input, creating a bottleneck in the process due to the lack of trained radiologists and pathologists. 
This is driving the trend towards unsupervised learning techniques に where salient features are 
recognised without human intervention に as well as the use of computer-generated training data 
created through generative adversarial networks.  
 
A recent national initiative funded by UKRI is particularly relevant; Health Data Research UK is a 
collaboration of 22 universities and research institutes, clustered into six regions designed to use 
health data securely to derive new knowledge and scientific discovery.  The six new data centres will 
create a research infrastructure platform on which research with digital data can be streamlined and 
optimized. 
 
There is also a shift away from using training data comprising processed images that are optimised 
for human viewing only and towards integrating raw acquisition data and physics models of the 
acquisition into the AI workflow. This would allow the creation of homogenised image datasets and 
their direct optimisation for diagnosis and treatment planning. There are also issues around 
interoperability and regional variations; an algorithm that works with data generated on one make 
of machine may not perform as well with images gathered from another.   
 
Despite the enthusiasm for developing AI-based imaging tools, rigorous clinical validation of these 
technologies remains a major challenge [3]. Unlike pharmaceutical companies, which must navigate 
a highly complex and well-established regulatory environment in order to gain approval for novel 
therapies, the regulatory framework for AI-based clinical technologies is still playing catch-up. Any 
validation test should be appropriate to the level of risk involved. For example, an algorithm 
designed to triage patients in a fracture clinic can tolerate more error than one designed to assess 
correct placement of a nasogastric feeding tube, where the outcomes of misplacement are life-
threatening. Therefore, there is a critical need for the development of robustness measures and 
uncertainty quantification for AI techniques and their requirements in varying clinical settings. 
 
Local differences in practice and patient populations also pose challenges; will a tool that has been 
developed using a population of breast cancer patients in Scotland be relevant to women in the 
southern states of the USA, or even in the south of England? Training and test datasets therefore 
need to be truly representative of the patient population to which the algorithm will be applied, or 
the specific patient population should be specified as part of the regulatory process. It is possible to 
ｷﾏ;ｪｷﾐW ; ゲﾗﾉ┌デｷﾗﾐ aﾗヴ DL デWIｴﾐﾗﾉﾗｪｷWゲ ┘ｴWヴW デｴWヴW ｷゲ ; IﾗヴW ;ﾉｪﾗヴｷデｴﾏ ┘ｷデｴ け;SS-ﾗﾐゲげ allowing for 
domain adaptation and consequently account for these local variations. 
 
Replication and reproducibility are significant concerns for clinical validation, particularly for results 
produced by proprietary algorithms generated by commercial organisations that are reluctant to 
ヴW┗W;ﾉ デｴWｷヴ けゲヮWIｷ;ﾉ ゲ;┌IWげく The benchmark for all AI imaging technologies should therefore be 
published, peer reviewed clinical trials, with as much transparency around the methodology, 
algorithm, training and test datasets and possible sources of bias as possible. There should also be 
an accurate characterisation of failure cases: it is just as important to understand ;ﾐ┞ けHﾉｷﾐS ゲヮﾗデゲげ as 
it is to demonstrate an impressive detection rate. The need to develop robust methods for 
evaluating the clinical utility of AI algorithms in imaging is therefore clear and, working with 
partners, the NIHR is reviewing processes and novel approaches to evaluation which will increasingly 
characterise this important area. 
 
As more AI-based platforms come to market, a concerted effort needs to be put into establishing 
standardised independent test datasets to demonstrate accuracy, sensitivity and specificity, 
analogous to the validation and quality control panels that are available for molecular diagnostics. 
These must be large enough to ;┗ﾗｷS デｴW ヮヴﾗHﾉWﾏ ﾗa けﾉW;ヴﾐｷﾐｪ デﾗ デｴW デWゲデげ ﾗヴ ﾗ┗Wヴaｷデデｷﾐg and allow for 
frequent retesting. 
 
While it is important that any regulatory processes do not create an unnecessary barrier to clinical 
use, it is vital that there is adequate oversight to ensure that AI technologies are safe, effective and 
accepted by patients and the public. MLっDL ゲﾗaデ┘;ヴW ｷゲ ﾉｷﾆWﾉ┞ デﾗ a;ﾉﾉ ┌ﾐSWヴ デｴW H;ﾐﾐWヴ ﾗa けﾏWSｷI;ﾉ 
SW┗ｷIWゲげ ;ﾐS ┘ｷﾉﾉ デｴWヴWaﾗヴW HW ゲ┌HﾃWIデ デﾗ ｴ;┗ｷﾐｪ デﾗ ｪ;ｷﾐ CE ;IIヴWSｷデ;デｷﾗﾐ ｷﾐ E┌ヴﾗヮW ﾗヴ FDA ;ヮヮヴﾗ┗;ﾉ ｷﾐ 
the US, which brings a requirement for post-marketing surveillance. It is also necessary to consider 
regular retesting and revalidation of AI-based algorithms. Several new AI tools have gained CE marks 
and FDA approval based on scant and often unpublished clinical data, and there are concerns that a 
failure to properly validate and monitor the application of these technologies in the real world could 
lead to potentially serious errors, risking the loss of public and professional trust. 
 
The British Standards Institute (BSI, Medicines & Healthcare products Regulatory Agency (MHRA) 
and the Association for the Advancement of Medical Instrumentation (AAMI) have now published a 
joint report on Machine Learning in Healthcare summarising the key recommendations based on the 
UK and US workshops held [9]. Further work, including participatory workshops, is planned aimed at 
developing approaches to regulation.  
 
Data governance 
Patient-derived data lies at the heart of any AI-based imaging system and is therefore subject to 
informed consent, national legal and regulatory frameworks, and societal norms. The introduction of 
the EU General Data Protection Regulation (GDPR) has clarified the requirements for organisations 
that gather and process personal data and, in our view, has been an enabler of research. However, 
there is still much confusion among the research community about how to navigate through the 
regulatory process に particularly for small commercial organisations に and further advice from 
regulatory bodies such as the UK Health Research Authority (HRA) would be welcome. There would 
also be value in the development of standardised national and international data-sharing 
agreements and contracts, which are already becoming common in pharmaceutical drug 
development and trials.  
 
AI research in medical imaging would benefit from new models for data accessibility, moving from 
the idea of data sharing to one of data access. Several academic and commercial organisations have 
accumulated extremely large datasets that could be of great use to the research community, and we 
would all benefit from the development of platforms that allow researchers to come and use 
cleaned, curated data within an organisational firewall with the appropriate permissions. This would 
have the advantage of democratising data science, reducing barriers to entry for small organisations 
and countries with less investment in their health data infrastructure. 
 
Public trust 
Patients should be at the heart of research, not only as beneficiaries of these new technologies but 
also as partners and participants at all stages of the process from design to delivery に a principle that 
lies at the heart of the NIHR. As well as being ethically correct, patient and public engagement and 
involvement makes research more effective, encouraging trial participation and retention and 
ensuring that the results of research are more likely to bring meaningful benefits. Despite recent 
high-profile scandals around the mis-use and leakage of personal data, the UK public remains 
broadly supportive of the use of patient data for medical research, even by commercial 
organisations [10]. However, levels of public trust are likely to vary by country and are currently 
being investigated through programmes such as the Wellcome Trust Global Monitor [11].  
 
However, just as what was acceptable practice in medical research fifty years ago is looked upon 
with horror today, we should be mindful that attitudes can change over time. There is a growing 
public suspicion of large privately-owned technology companies that gather and control personal 
data, whose priorities ultimately lie with their owners or shareholders rather than patients and the 
public, and the AI research community should continue to actively engage with patients and the 
public to monitor their concerns. For example, it is currently accepted that patients should not 
receive financial reimbursement for the use of their data or a share of the profit from any 
commercial product derived from it. That may change with the advent of blockchain technologies 
allowing individuals to control access to their personal data or even monetise it, as we are starting to 
see in the field of genomics, which are likely to impact upon public trust [12]. 
 
Finally, academic and industry researchers should consider how to deliver effective communication 
about AI-based technologies to patients, public and health professionals. It may not be necessary to 
IﾗﾏヮﾉWデWﾉ┞ W┝ヮﾉ;ｷﾐ デｴW けHﾉ;Iﾆ Hﾗ┝げ ﾗa W;Iｴ ;ﾉｪﾗヴｷデｴﾏ に after all, we do not expect doctors or patients 
to know the precise biological mode of action of every drug に but efforts need to be made to show 
how these tools work, the data that they are derived from, and their benefits and limitations. 
Building a culture of transparency and public understanding around the use of AI in medical imaging 
will help to secure trust and confidence in this exciting field as it moves into the future.  
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